39 related articles for article (PubMed ID: 15887215)
1. DNA sequence analysis of 1-nitropyrene-4,5-oxide and 1-nitropyrene-9,10-oxide induced mutations in the hprt gene of Chinese hamster ovary cells.
Kim HJ; Kim TH; Lee SY; Lee DH; Kim SI; Pfeifer GP; Kim SK; Lee CS
Mol Cells; 2005 Feb; 19(1):114-23. PubMed ID: 15750348
[TBL] [Abstract][Full Text] [Related]
2. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
[TBL] [Abstract][Full Text] [Related]
3. Cancer Cells Upregulate Tau to Gain Resistance to DNA Damaging Agents.
Rico T; Denechaud M; Caillierez R; Comptdaer T; Adriaenssens E; Buée L; Lefebvre B
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612113
[TBL] [Abstract][Full Text] [Related]
4. A Toxic Friend: Genotoxic and Mutagenic Activity of the Probiotic Strain Escherichia coli Nissle 1917.
Nougayrède JP; Chagneau CV; Motta JP; Bossuet-Greif N; Belloy M; Taieb F; Gratadoux JJ; Thomas M; Langella P; Oswald E
mSphere; 2021 Aug; 6(4):e0062421. PubMed ID: 34378987
[TBL] [Abstract][Full Text] [Related]
5. Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches.
Laprovitera N; Salamon I; Gelsomino F; Porcellini E; Riefolo M; Garonzi M; Tononi P; Valente S; Sabbioni S; Fontana F; Manaresi N; D'Errico A; Pantaleo MA; Ardizzoni A; Ferracin M
Front Cell Dev Biol; 2021; 9():666156. PubMed ID: 34178989
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms.
Szikriszt B; Póti Á; Németh E; Kanu N; Swanton C; Szüts D
Mutagenesis; 2021 Apr; 36(1):75-86. PubMed ID: 33502495
[TBL] [Abstract][Full Text] [Related]
7. A stapled POL κ peptide targets REV1 to inhibit mutagenic translesion synthesis.
Chatterjee N; D'Souza S; Shabab M; Harris CA; Hilinski GJ; Verdine GL; Walker GC
Environ Mol Mutagen; 2020 Oct; 61(8):830-836. PubMed ID: 32573829
[TBL] [Abstract][Full Text] [Related]
8. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.
Wojtaszek JL; Chatterjee N; Najeeb J; Ramos A; Lee M; Bian K; Xue JY; Fenton BA; Park H; Li D; Hemann MT; Hong J; Walker GC; Zhou P
Cell; 2019 Jun; 178(1):152-159.e11. PubMed ID: 31178121
[TBL] [Abstract][Full Text] [Related]
9. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
BMC Cancer; 2019 Mar; 19(1):255. PubMed ID: 30898102
[TBL] [Abstract][Full Text] [Related]
10. Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction.
Sail V; Rizzo AA; Chatterjee N; Dash RC; Ozen Z; Walker GC; Korzhnev DM; Hadden MK
ACS Chem Biol; 2017 Jul; 12(7):1903-1912. PubMed ID: 28541665
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive survey of the mutagenic impact of common cancer cytotoxics.
Szikriszt B; Póti Á; Pipek O; Krzystanek M; Kanu N; Molnár J; Ribli D; Szeltner Z; Tusnády GE; Csabai I; Szallasi Z; Swanton C; Szüts D
Genome Biol; 2016 May; 17():99. PubMed ID: 27161042
[TBL] [Abstract][Full Text] [Related]
12. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
Kawamoto Y; Tsuchihara K; Yoshino T; Ogasawara N; Kojima M; Takahashi M; Ochiai A; Bando H; Fuse N; Tahara M; Doi T; Esumi H; Komatsu Y; Ohtsu A
Br J Cancer; 2012 Jul; 107(2):340-4. PubMed ID: 22617127
[TBL] [Abstract][Full Text] [Related]
14. DNA polymerase eta and chemotherapeutic agents.
Chou KM
Antioxid Redox Signal; 2011 Jun; 14(12):2521-9. PubMed ID: 21050139
[TBL] [Abstract][Full Text] [Related]
15. Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model.
Kulkarni AD; van Ginkel PR; Darjatmoko SR; Lindstrom MJ; Albert DM
Br J Ophthalmol; 2009 Aug; 93(8):1105-8. PubMed ID: 19336429
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.
Sharma S; Gong P; Temple B; Bhattacharyya D; Dokholyan NV; Chaney SG
J Mol Biol; 2007 Nov; 373(5):1123-40. PubMed ID: 17900616
[TBL] [Abstract][Full Text] [Related]
17. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link.
Wu Y; Bhattacharyya D; King CL; Baskerville-Abraham I; Huh SH; Boysen G; Swenberg JA; Temple B; Campbell SL; Chaney SG
Biochemistry; 2007 Jun; 46(22):6477-87. PubMed ID: 17497831
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells.
Silva MJ; Costa P; Dias A; Valente M; Louro H; Boavida MG
Environ Mol Mutagen; 2005 Aug; 46(2):104-15. PubMed ID: 15887215
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts.
Bassett E; King NM; Bryant MF; Hector S; Pendyala L; Chaney SG; Cordeiro-Stone M
Cancer Res; 2004 Sep; 64(18):6469-75. PubMed ID: 15374956
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
